See More Hear More Watch More Hear More Get on iTunes
WSJ Daily Minute WSJMinute

Valeant bid for Allegan under scrutiny

Allergan’s fight against Valeant Pharmaceuticals’ $53 billion takeover bid highlights the acquirer’s hard-nosed strategy: buy up companies, shed most of their research operations, and make money selling their products. http://online.wsj.com/articles/bid-for-allergan-puts-valeants-research-and-development-cuts-under-scrutiny-1402443053?mod=WSJ_hp_LEFTWhatsNewsCollection

UP NEXT

More from